...
search icon
brns-img

Barinthus Biotherapeutics plc Share Price

BRNS
NMQ
$0.629
+$0
(0%)
1D
Industry: Biotechnology Sector: Health Care

Barinthus Biotherapeutics plc Analyst Forecast

Barinthus Biotherapeutics plc Share Price Chart

Barinthus Biotherapeutics plc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$25.68M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
142.63K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.65
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.56 L
$2.91 H
$0.629

About Barinthus Biotherapeutics plc, Common Stock

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Barinthus Biotherapeutics plc Stock Returns

Time FrameBRNSSectorS&P500
1-Week Return-10.78%-0.03%-1.38%
1-Month Return-17.17%0.59%-1.81%
3-Month Return-19.57%3.23%1.38%
6-Month Return-50.08%18.29%5.68%
1-Year Return-39.23%7.71%11.74%
3-Year Return-79.03%18.03%65.15%
5-Year Return-95.59%35.78%73.68%

Barinthus Biotherapeutics plc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue4.82M268.00K44.70M802.00K14.97M[{"date":"2020-12-31","value":10.78,"profit":true},{"date":"2021-12-31","value":0.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.79,"profit":true},{"date":"2024-12-31","value":33.49,"profit":true}]
Cost of Revenue14.39M--3.11K5.80M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":0.02,"profit":true},{"date":"2024-12-31","value":40.33,"profit":true}]
Gross Profit(9.57M)268.00K44.70M802.00K14.97M[{"date":"2020-12-31","value":-21.4,"profit":false},{"date":"2021-12-31","value":0.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.79,"profit":true},{"date":"2024-12-31","value":33.49,"profit":true}]
Gross Margin(198.42%)100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":-198.42,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses10.48M45.49M48.74M84.72M82.94M[{"date":"2020-12-31","value":12.37,"profit":true},{"date":"2021-12-31","value":53.7,"profit":true},{"date":"2022-12-31","value":57.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":97.9,"profit":true}]
Operating Income(20.05M)(45.22M)(4.04M)(83.91M)(67.97M)[{"date":"2020-12-31","value":-2004600000,"profit":false},{"date":"2021-12-31","value":-4522100000,"profit":false},{"date":"2022-12-31","value":-404100000,"profit":false},{"date":"2023-12-31","value":-8391400000,"profit":false},{"date":"2024-12-31","value":-6797000000,"profit":false}]
Total Non-Operating Income/Expense(1.39M)(8.59M)7.97M10.98M9.37M[{"date":"2020-12-31","value":-12.67,"profit":false},{"date":"2021-12-31","value":-78.17,"profit":false},{"date":"2022-12-31","value":72.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":85.3,"profit":true}]
Pre-Tax Income(17.84M)(51.14M)850.00K(76.52M)(61.23M)[{"date":"2020-12-31","value":-2098.59,"profit":false},{"date":"2021-12-31","value":-6016.47,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-9002.59,"profit":false},{"date":"2024-12-31","value":-7203.18,"profit":false}]
Income Taxes95.00K(28.00K)(4.47M)(3.08M)(44.00K)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-29.47,"profit":false},{"date":"2022-12-31","value":-4706.32,"profit":false},{"date":"2023-12-31","value":-3236.84,"profit":false},{"date":"2024-12-31","value":-46.32,"profit":false}]
Income After Taxes(17.93M)(51.11M)5.32M(73.45M)(61.18M)[{"date":"2020-12-31","value":-337.02,"profit":false},{"date":"2021-12-31","value":-960.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1380.32,"profit":false},{"date":"2024-12-31","value":-1149.84,"profit":false}]
Income From Continuous Operations(17.93M)(51.11M)5.32M(77.32M)(61.18M)[{"date":"2020-12-31","value":-337.03,"profit":false},{"date":"2021-12-31","value":-960.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1453.11,"profit":false},{"date":"2024-12-31","value":-1149.84,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(17.71M)(50.87M)5.34M(73.35M)(61.07M)[{"date":"2020-12-31","value":-331.45,"profit":false},{"date":"2021-12-31","value":-952.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1373.03,"profit":false},{"date":"2024-12-31","value":-1143.28,"profit":false}]
EPS (Diluted)-(3.05)0.13(1.92)(1.24)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-2346.15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1476.92,"profit":false},{"date":"2024-12-31","value":-955.46,"profit":false}]

Barinthus Biotherapeutics plc Ratios

Barinthus Biotherapeutics plc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

BRNS
Cash Ratio 6.88
Current Ratio 8.04

Barinthus Biotherapeutics plc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BRNS
ROA (LTM) -23.02%
ROE (LTM) -62.25%

Barinthus Biotherapeutics plc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BRNS
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Barinthus Biotherapeutics plc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BRNS
Trailing PE NM
Forward PE NM
P/S (TTM) 3.25
P/B 0.30
Price/FCF NM
EV/R 0.62
EV/Ebitda NM

FAQs

What is Barinthus Biotherapeutics plc share price today?

Barinthus Biotherapeutics plc (BRNS) share price today is $0.629

Can Indians buy Barinthus Biotherapeutics plc shares?

Yes, Indians can buy shares of Barinthus Biotherapeutics plc (BRNS) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BRNS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Barinthus Biotherapeutics plc be purchased?

Yes, you can purchase fractional shares of Barinthus Biotherapeutics plc (BRNS) via the Vested app. You can start investing in Barinthus Biotherapeutics plc (BRNS) with a minimum investment of $1.

How to invest in Barinthus Biotherapeutics plc shares from India?

You can invest in shares of Barinthus Biotherapeutics plc (BRNS) via Vested in three simple steps:

  • Click on Sign Up or Invest in BRNS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Barinthus Biotherapeutics plc shares
What is Barinthus Biotherapeutics plc 52-week high and low stock price?

The 52-week high price of Barinthus Biotherapeutics plc (BRNS) is $2.91. The 52-week low price of Barinthus Biotherapeutics plc (BRNS) is $0.56.

What is Barinthus Biotherapeutics plc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Barinthus Biotherapeutics plc (BRNS) is

What is Barinthus Biotherapeutics plc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Barinthus Biotherapeutics plc (BRNS) is 0.30

What is Barinthus Biotherapeutics plc dividend yield?

The dividend yield of Barinthus Biotherapeutics plc (BRNS) is 0.00%

What is the Market Cap of Barinthus Biotherapeutics plc?

The market capitalization of Barinthus Biotherapeutics plc (BRNS) is $25.68M

What is Barinthus Biotherapeutics plc's stock symbol?

The stock symbol (or ticker) of Barinthus Biotherapeutics plc is BRNS

How Can Investors Use Barinthus Biotherapeutics plc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Barinthus Biotherapeutics plc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Barinthus Biotherapeutics plc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Barinthus Biotherapeutics plc shares for Indian investors?

When investing in Barinthus Biotherapeutics plc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Barinthus Biotherapeutics plc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Barinthus Biotherapeutics plc share price with other stocks in the same sector?

Rather than merely checking the share price of Barinthus Biotherapeutics plc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Barinthus Biotherapeutics plc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top